GLP-1 receptor agonists and SGLT2 inhibitors demonstrated comparable cardiovascular benefits in patients with diabetes mellitus, including those with established cardiovascular disease.
Do GLP-1RAs provide comparable cardiovascular benefits to SGLT2Is in patients with diabetes mellitus?
In a real-world setting, GLP-1RAs and SGLT2Is demonstrate comparable cardiovascular benefits in patients with diabetes mellitus, supporting current guidelines.
Absolute Event Rate: 0% vs 0%
In this large-scale real-world study, individual GLP-1RAs and SGLT2Is exhibited largely comparable cardiovascular benefits, including in patients with established CVD. These findings align with network meta-analytic estimates from major cardiovascular outcome trials and broadly support current treatment guidelines. Clinical choices should be guided by relevant factors such as safety, adherence, tolerability, cost, and patient preference, where further work is needed.
Bu et al. (Wed,) reported a other. GLP-1 receptor agonists and SGLT2 inhibitors demonstrated comparable cardiovascular benefits in patients with diabetes mellitus, including those with established cardiovascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: